Intraoperative Radiotherapy for Locally Advanced Rectal Cancer by Kang, Min Kyu et al.
pISSN 2093-7822   eISSN 2093-7830
www.coloproctol.org
Journal of the Korean Society of
Coloproctology
www.coloproctol.org 274
Intraoperative Radiotherapy for Locally Advanced  
Rectal Cancer
Min Kyu Kang, Myung Se Kim, Jae Hwang Kim
1
Departments of Radiation Oncology and 
1Surgery, Yeungnam University College of Medicine, Daegu, Korea
Original Article
J Korean Soc Coloproctol 2010:26(4);274-278
DOI: 10.3393/jksc.2010.26.4.274
Purpose: Although intraoperative radiotherapy (IORT) is known to be a method that can reduce local recurrence in locally 
advanced colorectal cancer, it is not widely used. The aim of this study was to report our experience with IORT for locally 
advanced rectal cancer.
Methods: From 1991 to 1994, nine patients with locally advanced rectal cancer received IORT. External beam radiotherapy 
was given postoperatively in five patients and preoperatively in three. Seven patients received chemotherapy. IORT was done 
with 6-MeV or 9-MeV electrons, and 12 Gy was irradiated at the tumor bed. The median follow-up period was 84 months 
(range, 15 to 208 months).
Results: The median age of patients was 51 years (range, 42 to 73 years). All patients had advanced clinical T-stage (cT3/4) 
cancer. The overall and the disease-free survival rates were 66.7% and 66.7% at 5 years, respectively. One patient developed 
a local recurrence near the anastomosis site, which was out of the IORT field. Four patients died before the last follow-up; 
three from distant metastasis and one from secondary primary cancer. Adverse effects related to IORT did not occur.
Conclusion: Although the number of patients was small in this study, IORT is thought to be safe and effective in reducing 
local recurrence in locally advanced rectal cancer. However, the role of IORT should be refined in the era of preoperative 
radio-chemotherapy followed by total mesorectal excision.
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radio-chemotherapy is being widely used [2-4].
The local recurrence rate in patients treated with a total me-
sorectal excision is reported to be less than 10%, so the total 
mesorectal excision is used as the standard method [1, 5]. How-
ever, even in patients treated with a total mesorectal excision, 
28% showed a positive circumferential resection margin (nar-
rower than 1 mm). In most research, the local recurrence rate 
was high in patients with a positive circumferential margin [6]. 
Cases with a positive circumferential margin after surgery re-
quire a high dose greater than 60 Gy [7]. However, delivering 
a high radiation dose is difficult because of the possibility of 
side effects on the normal organs including the small intestine 
and bladder.
On the other hand, intraoperative radiotherapy (IORT) allows 
precise application of a high radiation dose with minimal ex-
posure of surrounding organs at the time of an operation [8, 
9]. A high local control rate can be achieved by using IORT, 
especially in patients with primary or recurrent tumors that 
are difficult to resect due to severe invasion into adjacent organs 
INTRODUCTION
The local recurrence rate in locally advanced rectal cancer was 
reported to be 16-29% in the past [1]. In order to reduce the 
recurrence rate in the pelvic cavity, preoperative or postopera-
tive external radiotherapy (45-50 Gy) was executed. However, 
recent studies have reported that preoperative radio-chemo-
therapy has more benefits on local control and side effects than 
postoperative radio-chemotherapy. As a result, preoperative 
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[10-17]. IORT has been executed at Yeungnam University 
Medical Center since 1991, and we already reported our early 
experience [12]. The aim of this study is to investigate the long-
term follow-up results of patients with primary locally advanc  - 
ed rectal cancer that were treated with IORT.
METHODS
Subject group
From May 1991 to July 1998, 14 colorectal patients were treated 
with IORT. Among these patients, 10 had primary locally ad-
vanced rectal cancer, 2 had primary locally advanced colon 
cancer, and 2 had recurrent rectal cancer. Subject patients for 
IORT treatment for primary locally advanced rectal cancer 
were cases where R0 excision was difficult due to suspicious 
T4 lesion or threatened mesorectal fascial invasion, and there 
were no distant metastasis. Among 10 patients with primary 
locally advanced rectal cancer, one patient was excluded for the 
analysis because that patient was lost to follow-up after a pal-
liative abdominoperineal resection. Thus, a total of 9 patients 
were analyzed in the present study.
Treatment method
At the beginning of IORT at our institution in 1991, we exe-
cuted external beam radiotherapy postoperatively after IORT, 
but since 1992, we have executed external beam radiotherapy 
preoperatively and IORT has been delivered intraoperatively. 
Every patient underwent a total mesorectal excision. Whole 
pelvic radiotherapy was executed in 8 patients. Among them, 
5 were irradiated postoperatively with 34.2 to 50.4 Gy (median, 
45 Gy) and 3 were irradiated preoperatively with 30 Gy. As 
chemotherapeutic drugs, a Mayo regimen using 5-fluoroura-
cil was administered in 4 patients, and oral 5-fluorouracil was 
administered in 3 patients. Two patients had both radiother-
apy and chemothearpy before surgery, and 6 patients were ad-
ministered chemotherapeutics postoperatively. The treatment 
method for each patient is thoroughly described in Table 1.
Although methods of IORT executed in our hospital have 
already been reported [18], a brief summary is follows: The 
operation and IORT were both executed in a radiotherapy 
treatment room where the linear accelerator is installed. Lo-
cations to be irradiated were determined by the surgeon and 
radiation oncologist after the primary tumor and lymph node 
had been removed. The IORT applicator was located in the 
pelvic cavity, avoiding the small intestine, the ureter, and ex-
cised part of the rectum. A dose of 12 Gy was irradiated by 
using a 6-MeV or a 9-MeV electron beam.
Follow-up
Follow-up was done as follows: A physical examination, blood 
test, and CEA test were done every 3 months for 2 years after 
the treatment, and after that, they were done every 6 months 
for the next 3 years. Simple chest radiography and abdomen 
and pelvis CT scans were done 2 times for the first year and 
once annually after that. Colonoscopy was done within one 
year after surgery and every 1-3 years after that. All the patients 
were followed with a median follow-up of 84 months (range, 
15 to 208 months).
Analysis
Complications related to surgery or radiotherapy were graded 
based on Common Toxicity Criteria for Adverse Events ver. 
3.0 as a standard. The survival period was defined as the time 
between the date of first treatment and the date of last follow-
up or death. The survival rate was calculated by using the Ka-
plan-Meier method. The relapse pattern was analyzed by sep-
Table 1. Patient/tumor characteristics and treatment results
Patients Sex Age
Pathologic
stage
a Treatment Surgery IORT (Gy)
External  
radiation (Gy)
Follow-up 
periods (mo)
Status
b Failures
1  F 61 III (C2) OP/IORT→CRCT APR 12  34.0   22 Dead Lung
2  M 73 II (B2) OP/IORT→RT LAR 12  50.4   52 Dead Lung
3  F 55 III (C2) OP/IORT→RT LAR 12           45  15 Dead Anastomosis 
site, Lung
4  F 50 II (B2) OP/IORT→RT→CT APR 12           45 208 Alive -
5  F 42 II (B2) OP/IORT→RT→CT LAR 12  39.6  150 Alive -
6  M 56 III (C2) RT→OP/IORT→CT APR 12  30.6 203 Alive -
7  M 42 III (C1) CRCT→OP/IORT→CT ULAR 12  30.4 189 Alive -
8  M 51 I (B1) CRCT→OP/IORT APR 12  30.6  84 Dead -
9  F 44 II (B2) OP/IORT→CT LAR 12  -  76 Alive -
APR, abdominoperineal resection; CRCT, concurrent radio-chemotherapy; CT, chemotherapy; IORT, intraoperative radiotherapy; LAR, low anterior resection; OP, operation; 
RT, radiotherapy; ULAR, ultra-low anterior resection.
aAJCC 2002 TNM staging (modified Astler-Coller stage); 
bPatients’ survival status at the last follow-up. Patients 1-3 died of systemic failure, and patient 8 died of gallblad-
der cancer as a secondary malignancy.Journal of the Korean Society of
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arating local and distant relapses. Intra-pelvic relapse was de-
fined as a local relapse, and extra-pelvic cavity relapse as dis-
tant metastasis.
RESULTS
Patient characteristics
Among 9 patients, 4 were males, and the age range of all pa-
tients was 42-73 years old (median, 51 years old). The tumor 
histology was an adenocarcinoma in all patients. The stages of 
the tumors for all patients who had immediate surgical treat-
ment after diagnosis were TNM stage II (4 patients) and III (2 
patients). Patients who underwent preoperative radiotherapy 
had ypI (1 patient) and ypIII stage (2 patients). The location 
of the tumor was 1-9 cm (median, 5 cm) from the anal verge. 
Four patients underwent an abdominoperineal resection, and 
5 patients underwent a low anterior resection. In all patients, 
proximal and distal margins were free for tumors, but in three 
patients, circumferential margins were positive for tumors 
(within 1 mm).
Side effects
Grade III/IV toxicity occurred in one patient, who had surgi-
cal treatment for ileus and anastomosis stenosis. However, nei-
ther ureteral stricture nor neuropathy was found in any patients.
Relapse patterns
Relapse occurred in 3 patients, and the 5-year disease-free 
survival rate was 66.7% (Fig. 1). The most common relapse was 
distant metastasis, which was discovered 7-17 months after sur-
gery. Two patients had lung metastasis, and 1 patient had liver 
metastasis. One patient had a local relapse in the proximal side 
of the anastomosis site, along with a distant metastasis that 
occurred 7 months after the surgery. However, no relapses were 
noted in the IORT field.
Survival rate
A total of 4 patients died before the last follow-up. Three pa-
tients died of distant metastasis and progress of the disease. 
The other patient had gallbladder cancer that occurred 74 
months after surgery and died 8 months later. The 5-year and 
the 10-year overall survival rates were 66.7% and 53.3%, respec-
tively (Fig. 1).
DISCUSSION
Although the number of patients who underwent IORT was 
small, there were no IORT-related side effects or relapse in the 
IORT field. The local relapse rate for cT3/4 rectal cancer was 
2-13% in other research [10, 11, 13-18]. In cases where com-
plete excision was possible, the local relapse rate was 2-6%, and 
relapses occurred mostly away from the IORT irradiation site.
Common side effects that occur if IORT is executed inside 
the pelvic cavity are neuropathy and ureteral stricture. Neu-
ropathy is mostly related with IORT dose and is rare at a dose 
of 12 Gy, which was the dose used in the current study. One 
patient out of 29 who underwent preoperative or postopera-
tive external radiotherapy (45-55 Gy) and IORT (7.5-12.5 Gy) 
was reported to have grade-II neuropathy [10, 19]. The ureter 
has more resistance to radiation than the peripheral nerve, and 
in animal experiments, fibrosis or stricture occurred when a 
radiation dose greater than 30 Gy was delivered [19]. However, 
ureteral stricture can be treated with a stent, so the ureter near 
the tumor does not have to be displaced from the irradiation 
field. Accordingly, adding IORT of 12 Gy to external radiother-
apy of 45-50 Gy is thought to be safe for normal tissue inside 
the pelvic cavity.
A positive resection margin or the presence of a residual tu-
mor is an indication for IORT because of the high rate of local 
relapse. The Mayo clinic uses a dose of 7.5-10 Gy when the re-
section margin is negative, 10-12.5 Gy when the resection mar-
gin is microscopically positive, 15 Gy when the residual tumor 
is less than or equal to 2 cm, 17.5-20 Gy when the residual tu-
mor is greater than 2 cm, and 45-55 Gy as preoperative or post-
operative external radiotherapy [10]. There was difference in 
the local relapse rate depending on the extent of the residual 
tumor; 5% for microscopically positive residual tumors and 
25% for gross residual tumors. And there were no relapses 
within the IORT field, except 1 patient where the tumor was 
not completely excised. On the other hand, patients who had 
incomplete removal and underwent only external radiother-
apy had a high local relapse rate of 76% in the same institute 
[20].
Preoperative radio-chemotherapy is used to increase the com-
plete excision rate in patients with locally advanced rectal can-
cer. According to following studies, additional IORT after suc-
Fig. 1. Survival rates of 9 patients who were treated with intraopera-
tive radiotherapy.
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cessful radical excision following preoperative radiotherapy 
helps increase local control [11, 13]. Massachusetts General 
Hospital executed 50.4 Gy preoperative radiotherapy and 10 to 
15 Gy IORT (mostly 15 Gy) in unresectable locally advanced 
rectal cancer cases [11]. The 5-year local control rate of 22 pa-
tients who had IORT after complete excision was 88%. On the 
other hand, the 5-year local control rate of 13 patients who did 
not have IORT because of not having adhesion and resection 
margin greater than 5 mm was 71%. Ratto et al. [13] executed 
preoperative radio-chemotherapy of 45 Gy in cT4 and cN3 
patients (40 cT4 patients and 3 cT3 patients) and a total me-
sorectal excision. Radical excision was possible in 88% of the 
patients, and IORT (10-15 Gy) was done in 19 patients. The 
5-year local control rates of the IORT-irradiated group and 
the non-IORT-irradiated group were 90.9% and 56.7%, respec-
tively. There were no relapses within the IORT field.
Among studies on locally advanced rectal cancer, there were 
differences between studies where IORT was executed after 
preoperative radio-chemotherapy [14-16] and studies where 
IORT was not executed (phase III study) [4]. The local recur-
rence rate in the IORT group was lower than that in the non-
IORT group (preoperative radio-chemotherapy only group) 
(2-3% vs. 6%) in spite of the higher number of cT4 patients 
and the lower rate of total mesorectal excision in the IORT 
group. Although we cannot directly compare the results from 
studies with different subject patients, according to the facts 
above, preoperative radio-chemotherapy followed by IORT 
seems to be able to further increase the local control rate. How-
ever, a total mesorectal excision is being used as the standard, 
so it is difficult to say that IORT following radio-chemother-
apy is necessarily beneficial.
However, according to the meta-analysis results for the rela-
tionship between the circumferential resection margin and the 
local relapse rate, patients needing IORT can be sorted out [6]. 
In this study, in cases of positive circumferential resection mar-
gins, the relative risks of local relapse in the group that under-
went preoperative radiotherapy and in the group that did not 
were 6.3 (95% confidence interval [CI], 3.7 to 16.7) and 2.0 
(95% CI, 1.4 to 2.9), respectively. Because of the high local re-
lapse rate in patients with positive resection margins, additional 
radiotherapy after surgery might be helpful. However, using 
external radiotherapy is limited due to the normal tissue tol-
erance, whereas IORT can be used safely and selectively. The 
sensitivity and positive predictive value of magnetic resonance 
imaging (MRI) on mesorectal fascia involvement in rectal can-
cer treated with preoperative radiotherapy are 75-100% and 
57-92%, respectively [21, 22]. Although more studies are needed, 
MRI could be a help in selecting patients for whom increased 
local control rate can be achieved through the use of IORT.
According to the long-term follow-up results from a small 
group of patients with locally advanced rectal cancer who was 
treated with IORT, local relapse was not observed in the IORT 
field. Although there have been no case-control studies with 
large subject groups, based on our experience and on the results 
of other studies, adding IORT to preoperative or postoperative 
radio-chemotherapy will increase the local control rate with-
out major complications. However, more studies are needed 
to determine the effects of IORT on patients with resectable 
locally advanced rectal cancer who are treated with preopera-
tive radio-chemotherapy and a total mesorectal excision.
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